← Eichor
Condition: Neuromyelitis Optica Spectrum Disorder Nmosd Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuromyelitis Optica Spectrum Disorder Nmosd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Phase N/A · 1 location(s) · Tongji Hospital · NCT06885957Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
NA · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06780709Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte My
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06865274A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Phase 2/Phase 3 · 51 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06413654Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
EARLY_Phase 1 · 4 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05145361Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Phase N/A · 33 location(s) · Alexion Pharmaceuticals, Inc. · NCT05966467Ofatumumab in AQP4-IgG Seropositive NMOSD
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT05504694Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optic
NA · 1 location(s) · Tang-Du Hospital · NCT07377305Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Phase 2 · 19 location(s) · Amgen · NCT05549258Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Phase 3 · 1 location(s) · Tianjin Medical University General Hospital · NCT07420296Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07410039Cohort Study on Neuroimmune Diseases in the Reproductive Age
Phase N/A · 1 location(s) · Third Affiliated Hospital, Sun Yat-Sen University · NCT07653984Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn
Phase N/A · 1 location(s) · Amgen · NCT05909761Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NA · 22 location(s) · Ad scientiam · NCT05566769A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
Phase 3 · 13 location(s) · Hoffmann-La Roche · NCT05199688A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
Phase 2 · 1 location(s) · Guangzhou JOYO Pharma Co., Ltd · NCT06697535A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1 · 1 location(s) · RenJi Hospital · NCT06249438Efgartigimod for the Treatment of Acute Optic Neuritis
Phase 2 · 2 location(s) · Anastasia Vishnevetsky, MD, MPH · NCT06453694Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.